ANTIFUNGAL RESISTANCE IN DERMATOMYCOSES: CURRENT TREATMENT CHALLENGES | Dermatovenereology and aesthetic medicine

ANTIFUNGAL RESISTANCE IN DERMATOMYCOSES: CURRENT TREATMENT CHALLENGES

Digital Object Identifier (DOI) https://doi.org/10.67620/dermajournal.1730075
Maxmudjonov M.1
Received Sep 26, 2026
Revised Oct 11, 2026
Published Oct 16, 2026

Annotatsiya

Dermatomycoses affect an estimated 20–25% of the global population. Over the past five years, this burden has been compounded by the rapid emergence of Trichophyton indotineae, a terbinafine-resistant dermatophyte first identified on the Indian subcontinent and now documented across more than 40 countries (da Silva et al., 2026). Reported resistance rates for this pathogen vary considerably across the literature, ranging from 5% to over 77%, a discrepancy risking misinterpretation as inconsistent evidence rather than a predictable consequence of study design.

Kalit so'zlar

—

Maqolaga iqtibos keltirish andozasi

APA style
Maxmudjonov M. (2026). ANTIFUNGAL RESISTANCE IN DERMATOMYCOSES: CURRENT TREATMENT CHALLENGES. *Dermatovenereology and aesthetic medicine*, 17(3), 112. https://doi.org/10.67620/dermajournal.1730075